The Role of α7-Nicotinic Acetylcholine Receptors in the Pathophysiology and Treatment of Parkinson’s Disease
Open Access
- 30 March 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3210
Abstract
The α7 nicotinic acetylcholine receptor (α7-nAChR) is a pivotal regulator of neurotransmission, neuroprotection, and immune modulation in the central nervous system. This review explores its structural and functional attributes, highlighting its therapeutic potential in neurodegenerative disorders, particularly Parkinson’s disease (PD). α7-nAChRs mediate synaptic plasticity, modulate inflammatory responses, and influence dopamine release, positioning them as a promising pharmacological target. Positive allosteric modulators (PAMs) enhance α7-nAChR activity mainly by reducing desensitization, offering a superior therapeutic approach compared with direct agonists. Emerging preclinical studies suggest that α7-nAChR activation mitigates dopaminergic neurodegeneration, improves L-dopa-induced dyskinesia, and reduces neuroinflammation. Despite promising findings, clinical trials have yielded mixed results, necessitating further research into optimizing α7-targeted therapies. This review underscores the significance of α7-nAChRs in PD pathophysiology and highlights future directions for their translational potential in neuroprotection and symptomatic relief.Keywords
Funding Information
- DMU
This publication has 158 references indexed in Scilit:
- α7 nicotinic receptor agonists reduce levodopa‐induced dyskinesias with severe nigrostriatal damageMovement Disorders, 2015
- ABT‐089 and ABT‐894 reduce levodopa‐induced dyskinesias in a monkey model of Parkinson's diseaseMovement Disorders, 2014
- Parkinson’s Disease2012
- Meta‐analysis of early nonmotor features and risk factors for Parkinson diseaseAnnals of Neurology, 2012
- Parkinson's disease, proteins, and prions: MilestonesMovement Disorders, 2011
- Advances in environmental epidemiologyMovement Disorders, 2010
- Nicotine and Parkinson's disease: Implications for therapyMovement Disorders, 2008
- Smoking and Parkinson's disease: Systematic review of prospective studiesMovement Disorders, 2004
- Cellular Expression of α7 Nicotinic Acetylcholine Receptor Protein in the Temporal Cortex in Alzheimer's and Parkinson's Disease— A Stereological ApproachNeurobiology of Disease, 2000
- Genomic Organization and Partial Duplication of the Human α7 Neuronal Nicotinic Acetylcholine Receptor Gene (CHRNA7)Genomics, 1998